Digital Therapeutics for Substance Use Disorders: Research Priorities and Clinical Validation

September 30, 2021
1:00 PM (EDT)

Loading Events
  • This event has passed.
Watch Now View Presentation Slides

Presenter(s): Will M. Aklin, PhD, Director, Behavioral Therapy Development Program, Division of Therapeutics and Medical Consequences (DTMC), NIH, National Institute on Drug Abuse (NIDA)

Target Audience: Physicians, nurse practitioners or other advanced practice nurses, PAs, and pharmacists.

Webinar Description: There are effective treatments for Substance Use Disorders (SUDs), though they do not work for all patients and efficacy decreases over the long-term. As evidenced during the COVID-19 pandemic, traditional methods of delivering treatment have limitations and can be difficult or even impossible to access. Thus, there is an urgent need for new therapeutic options. This webinar will highlight research to support the development of safe and effective Digital Therapeutics (DTx), discuss strategies to accelerate their delivery to patients, and improve SUD treatment outcomes. DTx, a subset of digital health, consists of high-quality software programs to prevent, manage, or treat medical conditions. DTx that meet the definition of a medical device go through an FDA regulatory review process to be legally marketed in the US. The ultimate goal of this webinar is to illuminate NIH-research priorities and clinically validated DTx options for patients with SUDs.

Educational Objectives:

  • Discern which technologies constitute digital therapeutics
  • Gain an understanding of digital therapeutics as stand-alone treatments or integrated with FDA-approved substance use disorder treatments
  • Learn about the FDA authorization process for digital therapeutics

Credit Designations Available: AMA PRA Category 1 Credit™, Nursing Contact Hours, AAPA Category 1 CME credit, Pharmacy CE credit

Continuing Education Information

Jointly Accredited ProviderIn support of improving patient care, American Academy of Addiction Psychiatry is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Designation Statement

American Academy of Addiction Psychiatry designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Designation Statement

American Academy of Addiction Psychiatry is an approved provider of nursing continuing education through AAAP’s Joint Accreditation provider #4008192. This activity is approved for up to 1 CNE credits.

PA Designation Statement

PA AAPA Category 1 CMEAmerican Academy of Addiction Psychiatry has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for a maximum of 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Pharmacy Designation Statement

This course has been approved for 1 hour of pharmacy continuing education credit. The approval number issued is Universal Activity Number: JA4008192-0000-21-020-H01-P

Other Health Professionals and Other Learners

Participants will receive a certificate stating this program is designated for 1 AMA PRA Category 1 Credits™. This credit is accepted by the AANP and the AAPA.

Details

Date:
September 30
Time:
1:00 pm - 2:00 pm
Event Category:

Other

Presenter
Will M. Aklin, PhD, Director, Behavioral Therapy Development Program, Division of Therapeutics and Medical Consequences (DTMC), NIH, National Institute on Drug Abuse (NIDA)
Time Zone
ET